|111.50||-0.3200||-0.29%||Vol 1.58M||1Y Perf -14.01%|
|Feb 2nd, 2023 11:32 DELAYED|
|-0.80 -0.72%||- -|
|Target Price||118.53||Analyst Rating||Strong Buy 1.41|
|Potential %||6.29||Finscreener Ranking||★★+ 47.62|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★★+ 48.51|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★★★ 57.38|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||★★★ 46.54|
|Price Range Ratio 52W %||48.43||Earnings Rating||Neutral|
|Market Cap||194.41B||Earnings Date||25th Jan 2023|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||0.90|
|EPS Growth Next 5 Years %||5.10|
|Avg. Weekly Volume||4.59M|
|Avg. Monthly Volume||5.00M|
|Avg. Quarterly Volume||4.69M|
Abbott Laboratories (NYSE: ABT) stock closed at 111.82 per share at the end of the most recent trading day (a 1.15% change compared to the prior day closing price) with a volume of 4.51M shares and market capitalization of 194.41B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 109000 people. Abbott Laboratories CEO is Robert B. Ford.
The one-year performance of Abbott Laboratories stock is -14.01%, while year-to-date (YTD) performance is 1.85%. ABT stock has a five-year performance of 81.26%. Its 52-week range is between 93.25 and 130.935, which gives ABT stock a 52-week price range ratio of 48.43%
Abbott Laboratories currently has a PE ratio of 25.40, a price-to-book (PB) ratio of 5.49, a price-to-sale (PS) ratio of 5.83, a price to cashflow ratio of 19.30, a PEG ratio of 2.32, a ROA of 11.66%, a ROC of 15.73% and a ROE of 24.34%. The company’s profit margin is 17.58%, its EBITDA margin is 29.30%, and its revenue ttm is $33.56 Billion , which makes it $19.25 revenue per share.
Of the last four earnings reports from Abbott Laboratories, there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.90 for the next earnings report. Abbott Laboratories’s next earnings report date is -.
The consensus rating of Wall Street analysts for Abbott Laboratories is Strong Buy (1.41), with a target price of $118.53, which is +6.29% compared to the current price. The earnings rating for Abbott Laboratories stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Abbott Laboratories has a dividend yield of 1.82% with a dividend per share of $2.04 and a payout ratio of 45.00%.
Abbott Laboratories has a Buy technical analysis rating based on Technical Indicators (ADX : 9.34, ATR14 : 2.01, CCI20 : -45.17, Chaikin Money Flow : 0.01, MACD : 0.54, Money Flow Index : 37.56, ROC : -1.49, RSI : 54.28, STOCH (14,3) : 50.60, STOCH RSI : 0.78, UO : 52.64, Williams %R : -49.40), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Abbott Laboratories in the last 12-months were: Andrea F. Wainer (Sold 456 shares of value $53 866 ), Christopher J. Calamari (Sold 706 shares of value $83 414 ), Daniel Gesua Sive Salvadori (Sold 1 550 shares of value $183 165 ), Daniel J. Starks (Sold 150 000 shares of value $15 990 972 ), Fernando Mateus (Sold 2 457 shares of value $267 943 ), Gregory A. Ahlberg (Sold 1 099 shares of value $129 847 ), Hubert L. Allen (Sold 1 450 shares of value $171 348 ), Jared L. Watkin (Sold 1 038 shares of value $122 589 ), John F. Ginascol (Sold 11 000 shares of value $1 235 520 ), Joseph J. Manning (Option Excercise at a value of $2 043 110), Joseph J. Manning (Sold 50 685 shares of value $5 378 990 ), Julie L. Tyler (Sold 715 shares of value $82 714 ), Lisa D. Earnhardt (Sold 943 shares of value $111 416 ), Louis H. Morrone (Sold 656 shares of value $77 513 ), Michael D. Dale (Sold 5 053 shares of value $592 413 ), Nancy Mckinstry (Option Excercise at a value of $187 394), Nancy Mckinstry (Sold 1 614 shares of value $187 910 ), Randel W. Woodgrift (Option Excercise at a value of $1 065 600), Randel W. Woodgrift (Sold 24 964 shares of value $2 825 952 ), Robert B. Ford (Option Excercise at a value of $4 121 870), Robert B. Ford (Sold 102 425 shares of value $10 765 154 ), Sammy Karam (Sold 4 200 shares of value $456 750 )
Sat, 28 Jan 2023 01:45 GMT Abbott Labs (ABT) Gets a Buy from RBC Capital- TipRanks. All rights reserved.
Fri, 21 Oct 2022 12:36 GMT Abbott Labs (ABT) Gets a Buy from Raymond James- TipRanks. All rights reserved.
Wed, 27 Jul 2022 16:49 GMT Abbott Labs (ABT) Receives a Buy from UBS- TipRanks. All rights reserved.
Wed, 20 Jul 2022 15:27 GMT Abbott Posts Q2 Beat & Raises EPS Guidance- TipRanks. All rights reserved.
Fri, 15 Jul 2022 12:40 GMT Analysts Offer Insights on Healthcare Companies: Abbott Labs (ABT) and HCA Healthcare (HCA)- TipRanks. All rights reserved.
Thu, 14 Jul 2022 12:15 GMT Analysts Are Bullish on Top Healthcare Stocks: Abbott Labs (ABT), CytomX Therapeutics (CTMX)- TipRanks. All rights reserved.
Mon, 11 Jul 2022 13:58 GMT Abbotts Sturgis Facility Restarts Operations- TipRanks. All rights reserved.
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.